Mavacamten

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Today, a brief rundown of news from Bristol Myers Squibb and Cytokinetics as well as updates from Disc Medicine and Teva Pharmaceutical that you may have missed.The Food and Drug Administration has accepted Bristol Myers Squibbs approval application for its experimental multiple myeloma drug iberdomide, setting a decision deadline of Aug. 17, the company said Tuesday. The drug, from a new class of protein-degrading treatments, is intended for use in combination with Johnson & Johnsons Darzalex and the steroid dexamethasone in people whose disease has advanced or become resistant to early lines of treatment. In a Phase 3 trial, iberdomide plus Darzalex and dexamethasone helped significantly more people with multiple myeloma become minimal residual disease negative compared to older combination treatment. Iberdomides progress is one of the most important events in Bristol Myers year as it tries to shake off a 2025 that included a round of cost cuts and clinical setbacks. Jonathan GardnerMeanwhile, the FDA rejected Disc Medicines application for accelerated approval of bitopertin,the company said last Friday, though it indicated that it could evaluate data from a Phase 3 study of the drug for the rare disease erythropoietic protoporphyria in a traditional setting. In a complete response letter, the FDA wrote that two trials of bitopertin confirmed the drugs benefit in lowering levels of protoporphyrin IX, a substance that builds up in the red blood cells of people with EPP and causes extreme sensitivity to light. However, the agency wrote there are uncertainties regarding whether lower levels of protoporphyrin IX correlated to meeting sunlight exposure endpoints laid out in one of Discs studies. The company received a national priority voucher last fall to speed up its review, though a report published by Stat Newsin the months following revealed skepticism over the drugs efficacy from Center for Biologics Evaluation and Research Director Vinay Prasad. Gwendolyn WuThe European Commission has approved Cytokinetics pill Myqorzo to treat the heart condition obstructive hypertrophic cardiomyopathy, the company said Tuesday. The approval for the 27 member countries of the European Union follows its U.S. OK by about two months. In the EU, Myqorzo could have some advantages over Bristol Myerscompeting drug Camzyos, including more flexible dosing and no requirement for genotyping,Stifel analyst James Condulis wrote in a note to clients. Camzyos, from the same class of drugs called cardiac myosin inhibitors, recorded sales of $1.1 billion in 2025, with its international sales growth outpacing that in the U.S. Jonathan GardnerSanofi and Teva Pharmaceutical said their experimental antibody drug for ulcerative colitis and Crohns disease, duvakitug, maintained its efficacy over 44 weeks in the long-term extension stage of a Phase 2 trial. Remission and response rates for the high dose of 900 milligrams improved at the 44-week endpoint for both conditions compared with those seen at the main, 14-week endpoint, Jefferies analyst Dennis Ding wrote in a note to clients. That response rate compares favorably to competing drugs from the TL1A class being developed by Merck & Co. and Roche, Ding wrote. Merck and Roche have advanced their drugs into Phase 3 development. Jonathan Gardner '

Its new partnership aims to improve decision-making, identify productivity opportunities and find more efficient trial designs at Bristol Myers Squibb.\n Bristol Myers Squibb is partnering up with Evinova’s AI clinical development platform across the Big Pharma company’s global portfolio in an effort to improve efficiency and cut costs.The agreement says that BMS will deploy Evinova’s \"cost optimizer\" module, which is part of the Swiss company\'s study designer solution. Evinova was launched by AstraZeneca in 2023 to advance digital health solutions, and its new BMS partnership aims to improve decision-making, identify productivity opportunities and find more efficient trial designs.BMS’ Chief Medical Officer and head of development, Cristian Massacesi, M.D., emphasized the urgency of the partnership to improve drug development. “For years, developing medicines has taken too long, cost too much money and mostly resulted in failure,” he said via release. “Digital tools and AI can help us overcome these limitations and lay the foundation for better health outcomes for countless individuals in the years to come.”BMS is looking to up its drug development productivity ahead of expected revenue declines within its legacy product portfolio, which includes blood thinner Eliquis and oncology drugs Revlimid and Pomalyst. Overall sales in BMS’ legacy portfolio fell 16% to $21.7 billion last year.The efforts are already starting to pay off. In 2025, products in BMS’ growth portfolio category represented more than half of the company’s performance and brought in $26.4 billion of the drugmaker’s total revenue of $48.2 billion.  In an investor presentation last year, BMS CEO Chris Boerner noted the performance of newer candidates melanoma med Opdualag, CAR-T Breyanzi and heart drug Camzyos, which each had a blockbuster year. Blood disorder treatment Reblozyl generated more than $2 billion in revenue last year as well.These novel treatments powered BMS to post fourth-quarter revenues of $12.5 billion last year, 2% above analysts’ expectations. The Evinova partnership could continue that shift to newer products and ultimately possibly boost the company’s overall sales, which saw a slight decline from $48.3 billion in 2024.